Target intelligence / Profile preview

Proteasome 20S subunit alpha 4 (PSMA4)

Target
PSMA4
Molecular classification
Enzyme, Proteolytic complex subunit, Peptidase T1A family
01

Overview

Proteasome 20S subunit alpha 4 (PSMA4) is a core component of the 20S proteasome, an ATP- and ubiquitin-dependent multicatalytic proteinase complex responsible for the regulated degradation of most intracellular proteins in eukaryotic cells. The 20S proteasome is composed of four stacked rings of 28 subunits (two rings of seven alpha subunits, two of seven beta subunits); PSMA4 is one of the alpha subunits forming the gates that regulate substrate entry to the proteolytic chamber. As part of the larger 26S proteasome complex, PSMA4 contributes to protein homeostasis by removing misfolded, damaged, or unneeded proteins. It plays key roles in cell cycle control, antigen processing for MHC class I presentation, and embryonic development, among others. PSMA4 and the proteasome are implicated in various diseases, most notably cancer and neurodegenerative diseases, and are important therapeutic targets for clinically approved proteasome inhibitors such as bortezomib and carfilzomib.

Other names
Proteasome subunit alpha type-4PSMA4PSC9alpha-3HC9HsT17706Macropain subunit C9Multicatalytic endopeptidase complex subunit C9Proteasome component C9Proteasome subunit LProteasome subunit alpha-3Proteasome subunit α320S proteasome alpha 4 subunitC9
02

Mechanism of action

Inhibition of proteasomal proteolytic activity leading to accumulation of ubiquitinated proteins, induction of apoptosis, and impaired protein homeostasis

03

Biological functions

Protein degradationProtein homeostasisUbiquitin-dependent protein catabolismUbiquitin-independent protein catabolismRegulation of cell cycleAntigen processing (MHC class I pathway)Spermatogenesis
04

Disease associations

CancerNeurodegenerative diseaseCystic fibrosisParkinson’s diseaseOther protein aggregation disorders
05

Safety considerations

Cytotoxicity to noncancerous tissues (especially rapidly dividing cells)Risk of peripheral neuropathyMyelosuppressionPotential for off-target effects leading to protein aggregation/toxicity
06

Interacting drugs

Bortezomib

3 more in the full profile.

07

Biomarkers

Proteasome activity levels (for efficacy monitoring of proteasome inhibitors in oncology)PSMA4 mRNA or protein expression (research/experimental)

Beyond the preview

Go deeper on Proteasome 20S subunit alpha 4 (PSMA4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteasome 20S subunit alpha 4 (PSMA4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call